Skip to main content
Caplight Logo









MIMETAS

MIMETAS

Private
OegstgeestHealthcare & Life Scienceshttps://mimetas.com/

Last Round

Grant

Jul 7, 2024

Total Funding Raised

$32.96M

Company Overview

MIMETAS is a biotechnology company that develops and markets organ-on-a-chip products and 3D tissue models for drug development, compound testing, and research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

organ-on-a-chipmicrofluidicsdrug discoverytissue engineering3D cell culturetoxicology screeningpersonalized medicinedisease modelingphenotypic screeningcontract research organizationCROlab-on-a-chipin vitro modelshigh-throughput screeningpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MIMETAS Comparables

Compare MIMETAS with similar companies based on industry and business-model similarity.

MIMETAS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Emulate
91%
CN Bio
90%
InSphero
89%

MIMETAS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 7, 2024
GrantFeb 22, 2022
Series BApr 11, 2018
GrantDec 22, 2015
Series AOct 8, 2014
Grant
Sep 11, 2014

Key People

Founding team and executive leadership

Jos Joore

CEO And Co-founder

Founding Team

Bas Trietsch

Chief Technology Officer

Executive Team

MIMETAS Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2025

    Attended SLAS 2025 and launched new OrganoPlate UniFlow technology.

  • Jan 27, 2025

    OrganoPlate UniFlow technology unveiled at SLAS 2025.

Recent news

Latest coverage and updates

  • is_developingSep 20, 2026

    Mimetas B.V is developing integrated product and service workflows.

  • is_developingAug 10, 2026

    MIMETAS - The Organ on a Chip Company is developing scalable organ-on-a-chip platforms and human tissue models on Aug 10th '26.

MIMETAS Filings

Explore SEC and related filing metadata, where available.

MIMETAS filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MIMETAS's valuation, stock price, and market status.

Is MIMETAS a public or private company?

MIMETAS is a private company.

What is the current stock price of MIMETAS?

MIMETAS is a private company with no public stock price. No recent secondary market data is available.

How much is MIMETAS worth (valuation)?

Valuation information for MIMETAS is not publicly available.

Can I buy MIMETAS stock?

MIMETAS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MIMETAS's last funding round?

MIMETAS's most recent funding round was Grant on July 7, 2024.

Who are the main investors in MIMETAS?

Key investors in MIMETAS include European Commission (Horizon Europe), NC3Rs.

Will MIMETAS IPO soon?

No public IPO plans have been announced for MIMETAS.

How can I track MIMETAS secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MIMETAS's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersOegstgeest
Employee Range81
Year Founded2013
Last FundingJul 7, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?